ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > If you think you're cynical enough then you're naive

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Jun 04, 2021 4:12pm

89 Views

Post# 33331749

RE:RE:RE:If you think you're cynical enough then you're naive

https://www.sedar.com/GetFile.do?lang=EN&docClass=13&issuerNo=00022789&issuerType=03&projectNo=03234444&docId=4982433[/img]

TopBroker wrote: You hit that one right on the head M101. Collusion and corruption in the pharmaceutical industry is like a pandemic and anyone who thinks differently does not know how much money U.S lobbyists make. By the way PMN will not issue another 300 million shares like one poster suggests, rather they have given first right of refusal to the FSG group for up to 50 million and no share price was established.

[/quote]

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China